Tumour-targeted nanomedicines: Principles and practice

British Journal of Cancer

Volumn 99, Issue 3, 2008, Pages 392-397

  Lammers, T ^a   Hennink, W E ^a   Storm, G ^a  

^a UTRECHT UNIVERSITY   (Netherlands)

Author keywords

Drug targeting; Liposomes; Nanomedicines; Polymers

Indexed keywords

ALLOVECTIN; ALPHA2A INTERFERON; ANTHRACYCLINE; ASPARAGINASE MACROGOL; BLEOMYCIN; CARMUSTINE; CISPLATIN; CREMOPHOR; DAUNORUBICIN; DENILEUKIN DIFTITOX; DEXTRAN; DOXORUBICIN; GEMTUZUMAB OZOGAMICIN; GENERIC DRUG; IBRITUMOMAB TIUXETAN; IMMUNOLIPOSOME; LE SN38; LERAFAON; LIPOPLEX; LIPOSOME; LURTOTECAN; MACROGOL; MCC 465; METHOTREXATE; MITOPODOZIDE; NANOPLATIN; NK 911; ONCO TCS; PACLITAXEL; PACLITAXEL POLIGLUMEX; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; PK 1; PK 2; POLY[N [2 (HYDROXYPROPYL)METHACRYLAMIDE]; POLYMER; PRODRUG; SGN 15; THERMODOX; UNINDEXED DRUG; VINCRISTINE; ZINOSTATIN;

ALOPECIA; ANGIOGENESIS; BLOOD VESSEL PERMEABILITY; BONE MARROW DEPRESSION; BREAST CANCER; CARDIOMYOPATHY; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DRUG COATING; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM COMPARISON; DRUG INDICATION; DRUG RESPONSE; DRUG TARGETING; HEART DISEASE; HUMAN; KAPOSI SARCOMA; LIPID BILAYER; LUNG NON SMALL CELL CANCER; MICELLE; NANOMEDICINE; NAUSEA; NEUTROPENIA; NONHUMAN; OVARY CANCER; PRIORITY JOURNAL; REVIEW; TUMOR;

ANTINEOPLASTIC AGENTS; DRUG DELIVERY SYSTEMS; HUMANS; LIPOSOMES; NANOMEDICINE; NEOPLASMS; POLYMERS;

EID: 48349107149     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6604483     Document Type: Review

References (32)

1. Allen TM (2002) Ligand-targeted therapeutics in anticancer therapy. Nat Rev Cancer 2: 750-763
2. Bai S, Thomas C, Rawat A, Ahsan F (2006) Recent progress in dendrimer-based nanocarriers. Crit Rev Ther Drug Carrier Syst 23: 437-495
3. Bangham AD, Standish MM, Watkins JC (1965) Diffusion of univalent ions across the lamellae of swollen phospholipids. J Mol Biol 13: 238-252
4. De Smedt SC, Demeester J, Hennink WE (2001) Cationic polymer based gene delivery systems. Pharm Res 17: 113-126
5. Dipetrillo T, Milas L, Evans D, Akerman P, Ng T, Miner T, Cruff D, Chauhan B, Iannitti D, Harrington D, Safran H (2006) Paclitaxel poliglumex (PPX-Xyotax) and concurrent radiation for esophageal and gastric cancer: a phase I study. Am J Clin Oncol 29: 376-379
6. Drummond DC, Meyer O, Hong K, Kirpotin DB, Papahadjopoulos D (1999) Optimizing liposomes for delivery of chemotherapeutic agents to solid tumours. Pharmacol Rev 51: 691-743
7. Duncan R (2006) Polymer conjugates as anticancer nanomedicines. Nat Rev Cancer 6: 688-701
8. Gradishar WJ, Tjulandin S, Davidson N, Shaw H, Desai N, Bhar P, Hawkins M, O'Shaughnessy J (2005) Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol 23: 7794-7803
9. Gregoriadis G (1976) The carrier potential of liposomes in biology and medicine. N Engl J Med 295: 765-770
10. Gupta B, Levchenko TS, Torchilin VP (2005) Intracellular delivery of large molecules and small particles by cell-penetrating proteins and peptides. Adv Drug Deliv Rev 57: 637-651
11. Hanahan D, Weinberg RA (2000) The hallmarks of cancer. Cell 100: 57-70
12. Harris L, Batist G, Belt R, Rovira D, Navari R, Azarnia N, Welles L, Winer E (2002) Liposome-encapsulated doxorubicin compared with conventional doxorubicin in a randomized multicenter trial as first-line therapy of metastatic breast carcinoma. Cancer 94: 25-36
13. Hofheinz RD, Gnad-Vogt SU, Beyer U, Hochhaus A (2005) Liposomal encapsulated anti-cancer drugs. Anticancer Drugs 16: 691-707
14. Kirpotin DB, Drummond DC, Shao Y, Shalaby MR, Hong K, Nielsen UB, Marks JD, Benz CC, Park JW (2006) Antibody targeting of long-circulating lipidic nanoparticles does not increase tumour localisation but does increase internalization in animal models. Cancer Res 66: 6732-6740
15. Lammers T, Peschke P, Kühnlein R, Subr V, Ulbrich K, Huber P, Hennink W, Storm G (2006) Effect of intratumoral injection on the biodistribution and the therapeutic potential of HPMA copolymer-based drug delivery systems. Neoplasia 8: 788-795
16. Lammers T, Subr V, Peschke P, Kühnlein R, Hennink WE, Ulbrich K, Kiessling F, Heilmann M, Debus J, Huber PE, Storm G (2008) Image-guided and passively tumor-targeted polymeric nanomedicines for radiochemotherapy. Brit J Cancer, accepted
17. Li C, Ke S, Wu QP, Tansey W, Hunter N, Buchmiller LM, Milas L, Charnsangavej C, Wallace S (2000) Tumor irradiation enhances the tumor-specific distribution of poly(L-glutamic acid)-conjugated paclitaxel and its antitumor efficacy. Clin Cancer Res 6: 2829-2834
18. Link JS, Waisman JR, Nguyen B, Jacobs CI (2007) Bevacizumab and albumin-bound Paclitaxel treatment in metastatic breast cancer. Clin Breast Cancer 7: 779-783
19. Maeda H, Wu J, Sawa T, Matsumura Y, Hori K (2000) Tumour vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Control Release 65: 271-284
20. Matsumura Y, Gotoh M, Muro K, Yamada Y, Shirao K, Shimada Y, Okuwa M, Matsumoto S, Miyata Y, Ohkura H, Chin K, Baba S, Yamao T, Kannami A, Takamatsu Y, Ito K, Takahashi K (2004) Phase I and pharmacokinetic study of MCC-465, a doxorubicin (DXR). encapsulated in PEG immunoliposome, in patients with metastatic stomach cancer. Ann Oncol 15: 517-525
21. Neri D, Bicknell R (2005) Tumour vascular targeting. Nat Rev Cancer 5: 436-446
22. Nishiyama N, Kataoka K (2006) Current state, achievements, and future prospects of polymeric micelles as nanocarriers for drug and gene delivery. Pharmacol Ther 112: 630-648
23. Northfelt DW, Dezube BJ, Thommes JA, Miller BJ, Fischl MA, Friedman-Kien A, Kaplan LD, Du Mond C, Mamelok RD, Henry DH (1998) Pegylated-liposomal doxorubicin versus doxorubicin, bleomycin, and vincristine in the treatment of AIDS-related Kaposi's sarcoma: results of a randomized phase III clinical trial. J Clin Oncol 16: 2445-2451
24. Park JW, Benz CC, Martin FJ (2004) Future directions of liposome- and immunoliposome-based cancer therapeutics. Semin Oncol 31-S13: 96-205
25. Ringsdorf H (1975) Structure and properties of pharmacologically active polymers. J Polymer Sci Polymer Symp 51: 135-153
26. Romberg B, Hennink WE, Storm G (2007) Sheddable coatings for long-circulating nanoparticles. Sheddable coatings for long-circulating nanoparticles. Pharm Res 25: 55-71
27. Schiffelers RM, Ansari A, Xu J, Zhou Q, Tang Q, Storm G, Molema G, Lu PY, Scaria PV, Woodle MC (2004) Cancer siRNA therapy by tumour selective delivery with ligand-targeted sterically stabilized nanoparticle. Nucleic Acids Res 32: e14
28. Schiffelers RM, Banciu M, Metselaar JM, Storm G (2006) Therapeutic application of long-circulating liposomal glucocorticoids in autoimmune diseases and cancer. J Liposome Res 16: 185-194
29. Sengupta S, Eavarone D, Capila I, Zhao G, Watson N, Kiziltepe T, Sasisekharan R (2005) Temporal targeting of tumour cells and neovasculature with a nanoscale delivery system. Nature 436: 568-572
30. Seymour LW, Ferry DR, Anderson D, Hesslewood S, Julyan PJ, Poyner R, Doran J, Young AM, Burtles S, Kerr DJ (2002) Hepatic drug targeting: phase I evaluation of polymer-bound doxorubicin. J Clin Oncol 20: 1668-1676
31. Torchilin VP (2005) Recent advances with liposomes as pharmaceutical carriers. Nat Rev Drug Discov 4: 145-160
32. Vasey PA, Kaye SB, Morrison R, Twelves C, Wilson P, Duncan R, Thomson AH, Murray LS, Hilditch TE, Murray T (1999) Phase I clinical and pharmacokinetic study of PK1 [N-(2-hydroxypropyl)methacrylamide copolymer doxorubicin]: first member of a new class of chemotherapeutic agents-drug-polymer conjugates. Clin Cancer Res 5: 83-94